Analysis
As of November 17, 2026, Isomorphic Labs has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, TechCrunch reported. Andreessen Horowitz joined as a new investor, and the company said the money will help take its drug candidates into clinical trials. Isomorphic Labs did not disclose its new valuation.
The round lands roughly six months after Isomorphic Labs' $2.1 billion Series B, which makes the Series C about 2.4 times the size of the previous raise. That is a comparison of capital raised, not of valuation: neither round's price has been published by the company.
What does Isomorphic Labs do?
Isomorphic Labs was spun out of Google DeepMind in 2021, and its own site says the AlphaFold breakthrough "inspired Sir Demis Hassabis to found Iso in 2021" (Isomorphic Labs). Hassabis is founder and CEO. TechCrunch reported that he stepped back from leading DeepMind to focus on drug discovery and became its chairman.
“The round lands roughly six months after Isomorphic Labs' $2.1 billion Series B, which makes the Series C about 2.4 times the size of the previous raise.”
The product is a drug-design engine that TechCrunch describes as using "a slew of simulation AI models" to design molecules. The company calls it IsoDDE in its Series B announcement. Isomorphic Labs has signed deals with Eli Lilly, Novartis and Johnson & Johnson, according to TechCrunch, though none of those deal values were stated in the coverage we opened. Per TechCrunch, the company has reported positive preclinical results in oncology and immunology. It has not yet put a drug into human trials, which is what this round is for.
How much has Isomorphic Labs raised?
The two rounds that the company itself has announced in 2026 total $7.1 billion: the $2.1 billion Series B and this $5 billion Series C.
The Series B was led by Thrive Capital, with existing backers Alphabet and GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund, per Isomorphic Labs' Series B announcement dated May 12, 2026.
Value Add VC data
- May 2026, Series B -- $2.1B at an undisclosed valuation, led by Thrive Capital (source)
- Nov 2026, Series C -- $5B at an undisclosed valuation, co-led by Greenoaks and Sequoia Capital (source)
No multiple of the prior mark is possible, because neither valuation is public. Bloomberg reported earlier this month that the company was seeking funding at a $50 billion valuation, as TechCrunch noted; that figure is a reported target, not a confirmed price. For scale, two rounds from the same day are each a tenth of Isomorphic's raise or less:
- Genesis AI -- $500 million Series A at $3.5 billion post-money, robotics
- Science Corp -- $400 million Series D at a reported $3.5 billion, vision chip
Who invested in Isomorphic Labs?
Greenoaks and Sequoia Capital co-led the Series C, with Andreessen Horowitz new to the cap table. Existing backers also wrote checks, including Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, per TechCrunch. TechCrunch names GV, CapitalG, Thrive, MGX, Temasek and the UK Sovereign AI Fund among the existing backers that invested again. Thrive led the May round but not this one.
AI drug discovery: what the headline misses
The bear case is the gap between capital and evidence. Isomorphic Labs now has $7.1 billion of announced 2026 funding and no disclosed human data. Preclinical results in oncology and immunology are early; human trials are where candidates get tested on safety and efficacy, and AI design does not skip them. The pharma partnerships help, but their economics were not disclosed, so outsiders cannot tell how much of the company's value rests on milestone payments versus wholly owned programs.
The comparison to the rest of biotech on this page is telling. Johnson & Johnson agreed to pay $2.2 billion upfront for Ollin Biosciences, a clinical-stage company. Isomorphic Labs raised more than twice that amount in one private round before reaching the clinic. The next date that matters is its first trial filing: until a drug designed by IsoDDE doses a patient, the $5 billion is a bet on Hassabis and AlphaFold, not on a product.